Dendritic cells: making progress with tumour regression?
Due to their potent ability to activate the immune system, dendritic cells (DC) are showing promise as potential adjuvants for tumour immunotherapy of cancer patients. However, little is known about the effect tumour cells can have on DC function. Indeed, the discovery of different DC subsets with different immunological functions indicates that the relationship between tumour cells and tumour-infiltrating DC subtypes is likely to be complex. There remains a lot to be understood about the effects of tumours on DC before we can expect to benefit from DC-based tumour immunotherapy of cancer patients. Here we review the recent advances being made in understanding DC phenotype and function in relation to interactions with different types of tumours.
Byrne
Scott N
SN
Department of Medicine (Dermatology), Melanoma and Skin Cancer Research Institute, Sydney Cancer Centre, Royal Prince Alfred Hospital at the University of Sydney, Australia.
Halliday
Gary M
GM
D000818:Animals; D018925:Chemokines / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D051379:Mice; D009365:Neoplasm Regression, Spontaneous / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D018925:Chemokines